M&A

Did Gilead overpay for Immunomedics? Trodelvy answered that $21B-dollar question at ESMO: analyst
Did Gilead overpay for Immunomedics? Trodelvy answered that $21B-dollar question at ESMO: analyst
Fierce Pharma
Gilead Sciences
Immunomedics
M&A
Trodelvy
ESMO
breast cancer
Flag link:
Is Illumina Making an $8 Billion Blunder?
Is Illumina Making an $8 Billion Blunder?
Motley Fool
Illumina
Grail
M&A
diagnostics
investors
Flag link:
Vifor Pharma Group announces successful sale of OM Pharma
Vifor Pharma Group announces successful sale of OM Pharma
Pharmaceutical Business Review
Vifor Pharma
OM Pharma
Optimus Holding
M&A
Flag link:
Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field
Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field
Fierce Biotech
Roche
M&A
Inflazome
inflammatory disease
Flag link:
Report: Illumina in Talks to Acquire Cancer Diagnostics Startup Grail
Report: Illumina in Talks to Acquire Cancer Diagnostics Startup Grail
Motley Fool
M&A
diagnostics
cancer diagnostics
cancer
oncology
Illumina
Grail
Flag link:
The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19
The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19
Endpoints
Nestle
M&A
Aimmune
Palforzia
COVID-19
pandemic
peanut allergy
Flag link:
Gilead to buy cancer drugmaker Immunomedics for $21B
Gilead to buy cancer drugmaker Immunomedics for $21B
BioPharma Dive
Gilead Sciences
M&A
cancer
Immunomedics
Flag link:
Takeda to sell another non-core portfolio for $260 million to Cheplapharm
Takeda to sell another non-core portfolio for $260 million to Cheplapharm
Pharmafile
Takeda
Cheplapharm
M&A
Flag link:
Ahead of merger with Pfizer's generic unit, Mylan makes $757M+ purchase for European thrombosis portfolio
Ahead of merger with Pfizer's generic unit, Mylan makes $757M+ purchase for European thrombosis portfolio
Endpoints
Mylan
Europe
generics
Aspen Pharmacare
M&A
thrombosis
Pfizer
Flag link:
J&J, free from rival bidders, made Momenta wait on $6.5B deal
J&J, free from rival bidders, made Momenta wait on $6.5B deal
Fierce Biotech
JNJ
Momenta Pharmaceuticals
M&A
Flag link:
Bayer Agrees To Buy Personalized Vitamin Company Care/of At $225 Million Valuation
Bayer Agrees To Buy Personalized Vitamin Company Care/of At $225 Million Valuation
Forbes
Bayer
M&A
Care/of
consumer health
Flag link:
Nestle pays $2 billion to secure Aimmune’s allergy treatment
Nestle pays $2 billion to secure Aimmune’s allergy treatment
CNBC
Aimmune
Nestle
M&A
peanut allergy
Palforzia
Flag link:
Ionis strikes deal to buy back lipid disease spinout Akcea
Ionis strikes deal to buy back lipid disease spinout Akcea
Fierce Biotech
Ionis Pharmaceuticals
Akcea Therapeutics
M&A
lipid disease
Flag link:
Acadia Pharma Acquires CerSci, Potential Pain Meds in $52.5M Buyout
Acadia Pharma Acquires CerSci, Potential Pain Meds in $52.5M Buyout
Xconomy
Acadia Pharmaceuticals
M&A
CerSci Therapeutics
post-surgical pain
nerve pain
Flag link:
Bristol Myers to buy Forbius in hunt for Opdivo-enhancing drugs
Bristol Myers to buy Forbius in hunt for Opdivo-enhancing drugs
Fierce Biotech
Bristol-Myers Squibb
M&A
Forbius
Opdivo
Flag link:
Court approves Otsuka’s bid to buy Proteus for $15M
Court approves Otsuka’s bid to buy Proteus for $15M
MedCity News
M&A
Otsuka
Proteus Digital Health
bankruptcy
patient adherence
Flag link:
J&J inks $6.5B Momenta buyout to bag autoimmune drug
J&J inks $6.5B Momenta buyout to bag autoimmune drug
Fierce Biotech
JNJ
Momenta Pharmaceuticals
M&A
myasthenia gravis
Flag link:
Takeda to sell Japan consumer health unit to Blackstone for $2B-plus: reports
Takeda to sell Japan consumer health unit to Blackstone for $2B-plus: reports
Fierce Pharma
Takeda
Blackstone Group
M&A
consumer health
Flag link:
Takeda offers Japanese sales, admin staffers early retirement in post-Shire slimdown
Takeda offers Japanese sales, admin staffers early retirement in post-Shire slimdown
Fierce Pharma
Takeda
Japan
early retirement
Shire
M&A
Flag link:
Chinook raises $106M in private placement as it prepares to close merger with Aduro
Chinook raises $106M in private placement as it prepares to close merger with Aduro
Endpoints
Chinook Therapeutics
Aduro BioTech
M&A
Flag link:

Pages